文献速递冠心病瓣膜病与结构性心脏病血脂与心血管预防

脂蛋白(a)、炎症与冠心病及主动脉瓣狭窄风险

Lipoprotein(a), Inflammation, and Risk of Coronary Artery Disease and Aortic Valve Stenosis.
PubMed 文献 · JAMA Cardiol · 2026-01-01

IMPORTANCE: Clinical heterogeneity exists among individuals with elevated lipoprotein(a) [Lp(a)] levels. Prior studies suggest that low-grade inflammation may modify this risk, but results remain conflicting.…

要点

  • Lp(a)≥125 nmol/L者占16.0%,IL-6最高四分位组Lp(a)相关冠心病HR为1.43。

核心结论

  • 在初级预防人群中,IL-6可修饰Lp(a)相关的新发冠心病风险,低炎症水平时关联风险较低。
  • IL-6可能是修饰Lp(a)相关冠心病风险的炎症风险生物标志物。
  • 炎症生物标志物未修饰Lp(a)相关的新发主动脉瓣狭窄风险。

研究设计与样本

  • 基于英国生物银行人群队列,招募时间2006年3月至2010年10月。
  • 纳入研究入组时接受血浆蛋白质组学分析且无 prevalent 冠心病或主动脉瓣狭窄的UK Biobank参与者。
  • 冠心病中位随访13.5(12.7-14.3)年,主动脉瓣狭窄中位随访13.6(12.9-14.4)年。
  • 采用多变量校正Cox比例风险模型检验Lp(a)与各炎症生物标志物的交互作用。

主要发现

  • 在测试的炎症生物标志物中,IL-6与新发冠心病和主动脉瓣狭窄的关联最强。
  • 无炎症生物标志物修饰Lp(a)相关的新发主动脉瓣狭窄风险。

临床怎么用

  • 对Lp(a)≥125 nmol/L的初级预防人群,可考虑检测IL-6以识别炎症水平较高、Lp(a)相关冠心病风险更高的个体。
  • IL-6水平较低的Lp(a)升高者,其Lp(a)相关冠心病关联风险相对较低。
  • 炎症生物标志物未显示修饰Lp(a)与主动脉瓣狭窄的关联,Lp(a)相关主动脉瓣狭窄风险评估不依赖上述炎症指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Clinical heterogeneity exists among individuals with elevated lipoprotein(a) [Lp(a)] levels. Prior studies suggest that low-grade inflammation may modify this risk, but results remain conflicting. OBJECTIVE: To test the hypothesis that inflammatory biomarkers may modify Lp(a)-associated risk for coronary artery disease (CAD) and aortic valve stenosis (AS) in a primary prevention population. DESIGN, SETTING, AND PARTICIPANTS: Recruitment occurred between March 2006 through October 2010 among a population-based cohort of UK adults. UK Biobank participants without prevalent CAD or AS who underwent plasma proteomic profiling at study entry were eligible for inclusion. Data were analyzed from June 2025 through April 2026. EXPOSURES: Lp(a) levels (<125 nmol/L vs ≥125 nmol/L) and inflammatory biomarkers interleukin 1β (IL-1β), IL-18, IL-6, and the neutrophil to lymphocyte ratio (NLR). MAIN OUTCOMES AND MEASURES: The primary outcome was the risk of incident CAD. The secondary outcome was the risk of incident AS. RESULTS: Among 43 512 UK Biobank participants, 6975 (16.0%) had Lp(a) levels of 125 nmol/L or higher, 24 079 (55.3%) were female, and overall mean (SD) age was 56.5 (8.2) years. Median (Q1-Q3) follow-up was 13.5 (12.7-14.3) years for incident CAD and 13.6 (12.9-14.4) years for incident AS. Multivariable-adjusted Cox proportional hazards models tested the interaction between Lp(a) levels and each inflammatory biomarker in relation to the primary and secondary outcomes. Among inflammatory biomarkers tested, IL-6 demonstrated the strongest association with both incident CAD and AS. IL-6 levels modified Lp(a)-associated risk for incident CAD (hazard ratio [HR] for Lp(a) ≥125 nmol/L vs <125 nmol/L in quartile 4 of IL-6: 1.43; 95% CI, 1.25-1.63 vs in quartile 1 of IL-6: HR, 1.09; 95% CI, 0.85-1.38; P for interaction = .008). The interaction between Lp(a) and the NLR (P for interaction = .02) was suggestive but not significant after adjustment for multiple testing. No inflammatory biomarkers modified Lp(a)-associated risk for AS. CONCLUSIONS AND RELEVANCE: In this primary prevention cohort study, Lp(a)-associated risk for incident CAD was modified by IL-6, with lower associated risk observed in the setting of lower inflammatory biomarker levels. These findings identify IL-6 as a biomarker of inflammatory risk that may modify Lp(a)-associated CAD risk.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Mohammadnia N, Li L, Ezzat D, et al. Lipoprotein(a), Inflammation, and Risk of Coronary Artery Disease and Aortic Valve Stenosis. JAMA Cardiol. 2026. PMID: 42340696. doi:10.1001/jamacardio.2026.1852

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。